Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 56,448	$ 67,166
Research and development related success payments and contingent consideration	38,007	120
General and administrative	16,269	16,766
Total operating expenses	110,724	84,052
Loss from operations	(110,724)	(84,052)
Interest income, net	3,034	1,976
Other income (expense), net	215	(47)
Net loss	$ (107,475)	$ (82,123)
Net loss per common share - basic	$ (0.49)	$ (0.43)
Net loss per common share - diluted	$ (0.49)	$ (0.43)
Weighted-average number of common shares - basic	217,290	191,228
Weighted-average number of common shares - diluted	217,290	191,228